69393-72-2

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
1,3-Benzodioxol-4-ol is utilized as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical structure allows it to be incorporated into a wide range of compounds, contributing to the development of new drugs and pesticides.
Used in Antioxidant Applications:
1,3-Benzodioxol-4-ol has been investigated for its potential antioxidant properties. It can be used as an antioxidant in various applications, such as in the food industry to prevent oxidation and spoilage, or in cosmetic products to protect against free radicals and promote skin health.
Used in Antimicrobial Applications:
1,3-Benzodioxol-4-ol has also been studied for its antimicrobial properties, making it a potential candidate for use in disinfectants, sanitizers, and preservatives. Its ability to inhibit the growth of microorganisms can be beneficial in various industries, including healthcare, food processing, and personal care products.
Used in Controlled Substance Regulation:
Due to its potential use in the illicit production of drugs such as MDMA, 1,3-Benzodioxol-4-ol is regulated as a controlled substance in some countries. This regulation aims to prevent its misuse and ensure that it is only used for legitimate purposes, such as in the synthesis of approved pharmaceuticals and agrochemicals.

Upstream product

• 4776-00-5 4-hydroxybenzo[d][1,3]dioxole-5-carboxylic acid 
• 87-66-1 2-hydroxyresorcinol 
• 74-95-3 1,1-dibromomethane 
• 7797-83-3 2H-benzo[d]1,3-dioxolane-4-carbaldehyde 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 1817-95-4 4-methoxy-benzo[1,3]dioxole 
• 934-00-9 3-methocycatechol 
• 610-02-6 2,3,4-trihydroxybenzoic acid 
• 24677-78-9 2,3-dihydroxybenzaldehyde 
• 75-11-6 diiodomethane 

Downstream Products

• 115943-52-7 4-(phenylmethoxy)-1,3-benzodioxole 
• 1817-95-4 4-methoxy-benzo[1,3]dioxole 
• 288395-76-6 C₂₉H₃₇NO₇Si 
• 288395-84-6 4-(1-Ethoxy-ethoxy)-benzo[1,3]dioxole-5-carboxylic acid [(1R,5R,6R)-5-(tert-butyl-dimethyl-silanyloxy)-7-oxa-bicyclo[4.1.0]hept-3-en-3-yl]-(4-methoxy-benzyl)-amide 
• 288395-81-3 (1R,2R,3S,4S,4aR,11bR)-1-benzyloxy-5-(4-methoxy-benzyl)-2,3,4-trihydroxy-7-methoxy-1,3,4,4a,5,11b-hexahydro-2H-[1,3]dioxolo[4,5-j]phenanthridin-6-one 
• 82299-37-4 benzyloxy-2 piperonal 
• 86319-72-4 2,3-methylenedioxy-1,4-benzoquinone 
• 115943-54-9 4-hydroxy-7-(phenylmethoxy)-1,3-benzodioxole 
• 115943-53-8 4-formyl-7-(phenylmethoxy)-1,3-benzodioxole 
• 92830-78-9 (benzyloxy-2 methylenedioxy-3,4 benzyl)-4 <(trimethoxy-3,4,5-phenyl)hydroxymethyl>-3 dihydro-3H-furannone-2 
• 82314-35-0 (5aS,8aR)-10-Benzyloxy-5-hydroxy-5-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-5aH-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6-one 
• 82299-45-4 (5aR,8aR)-10-Benzyloxy-5-(3,4,5-trimethoxy-phenyl)-5,8,8a,9-tetrahydro-5aH-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6-one 
• 477-50-9 (+/-)-iso β-peltatine 
• 82299-45-4 O-benzyl (+/-)-iso-β-peltatine 

Relevant academic research and scientific papers

VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule Vascular Adhesion Protein- 1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.

CONFORMATIONALLY-CONSTRAINED BIOISOSTERES OF CAFFEIC ACID, AND SYNTHESIS AND THERAPEUTIC USES

A method of treating a disease condition in a mammal comprising administering a pharmacologically effective amount of a therapeutic, wherein the therapeutic includes a bioisosteres of caffeic acid. A pharmaceutical composition for treating a disease condition in a mammal comprising a first therapeutic that includes a bioisosteres of caffeic acid, wherein the condition may be breast cancer, and the pharmaceutical composition may include a second therapeutic for the disease condition that is not a bioisosteres of caffeic acid.

TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Imidazo ring PAR4 antagonist and medical applications thereof

The invention relates to an imidazo ring compound represented by formula (I) or formula (II), or a pharmaceutically acceptable salt or ester or solvate thereof. The compound disclosed by the inventioncan be used for preparing medicines for preventing or treating thromboembolic diseases.

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Novel use of amine compounds

The invention provides a preparation method and novel use of amine compounds. Specifically, the invention provides compounds shown in the formula A or their optical isomers, racemes, solvates or pharmaceutically acceptable salts and a medical use thereof. The above compounds can be used for preparation of a pharmaceutical composition or a preparation. The pharmaceutical composition or preparationis used for (a) inhibiting a transient receptor potential channel protein TRPA1 and (b) treating diseases associated with the transient receptor potential channel protein, wherein each group is defined in the specification.

C70 Fullerene-Catalyzed Metal-Free Photocatalytic ipso-Hydroxylation of Aryl Boronic Acids: Synthesis of Phenols

A metal-free C70 fullerene-catalyzed method has been developed for the ipso-hydroxylation of aryl and heteroaryl boronic acids to corresponding phenols under photocatalytic conditions. The reaction proceeds under oxygen atmosphere and the mechanistic study revealed that C70 plays a critical role in the generation of reactive oxygen species in the presence of blue light. Reactions in the presence of 18O-labelled water and oxygen confirmed the generation of reactive oxygen species from oxygen molecule. Amine used as a reductant could be recovered in the form of imine. The current method is also applicable to the synthesis of aryl ethers in one-pot two-step process. (Figure presented.).

The palladium/norbornene-catalyzed: Ortho -silylmethylation reaction: A practical protocol for ortho -functionalized one-carbon homologation of aryl iodides

A palladium/norbornene-catalyzed ortho-silylmethylation reaction using of (iodomethyl)cyclohexyloxydimethylsilane as the electrophile was reported. The ((cyclohexyloxy)dimethylsilyl)methyl group was readily oxidized using the Fleming-Tamao process or by ceric ammonium nitrate to give benzylic alcohol derivatives. This method was successfully applied in a concise synthesis of a biaryl analogue of schisandrins.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2

The present invention relates to compounds of formula (I) wherein R1, R2, X, Y and Z are as defined in the specification.

Studies on the narciclasine alkaloids: Total synthesis of (+)- narciclasine and (+)-pancratistatin

Enantioselective total syntheses of the antimmor alkaloids, (+)- narciclasine and (+)-pancratistatin, are reported. These syntheses feature a stereo- and regiocontrolled aryl enamide photocyclization to construct a common, advanced intermediate possessing a transfused BC substructure. Differential functional group interchange in the C-ring of this phenanthridone core structure allows for the production of the two target natural products in enantiomerically pure form.